Dyne Therapeutics (NASDAQ:DYN) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a report issued on Wednesday,Benzinga reports. The firm currently has a $55.00 price target on the stock.

Several other equities research analysts also recently weighed in on DYN. Morgan Stanley upped their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. Piper Sandler reissued an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Guggenheim raised their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Finally, StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Stock Performance

DYN traded down $2.07 on Wednesday, reaching $32.06. 250,371 shares of the company’s stock were exchanged, compared to its average volume of 1,489,884. Dyne Therapeutics has a twelve month low of $9.76 and a twelve month high of $47.45. The company’s 50 day moving average is $32.64 and its 200-day moving average is $35.12. The company has a market cap of $3.22 billion, a price-to-earnings ratio of -9.59 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Sell-side analysts forecast that Dyne Therapeutics will post -2.99 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox bought 32,000 shares of the stock in a transaction on Wednesday, September 4th. The stock was purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at approximately $264,320. This trade represents a -100.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO John Cox bought 32,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at approximately $264,320. The trade was a -100.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 158,975 shares of company stock worth $5,693,789. 20.77% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC grew its position in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares during the last quarter. Quantbot Technologies LP acquired a new position in Dyne Therapeutics during the 3rd quarter valued at about $34,000. US Bancorp DE grew its position in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at approximately $62,000. Finally, KBC Group NV raised its holdings in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.